Stock LLY ELI LILLY AND COMPANY
Add to a list
To use this feature you must be a member
Log inSign up

Financials Eli Lilly and Company Deutsche Boerse AG

Equities

LLY

US5324571083

Pharmaceuticals

Real-time Estimate Tradegate
Other stock markets
 03:12:45 2024-05-02 pm EDT 		5-day change 1st Jan Change
707 EUR -2.74% Intraday chart for Eli Lilly and Company +2.16% +34.53%
02:24pm Novo Nordisk: Wegovy, Ozempic prices in US fell in Q1 RE
07:42am Obesity drugmaker Novo Nordisk raises outlook, Q1 profit beats forecast RE

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 126,190 153,067 250,419 347,613 524,224 699,390 - -
Enterprise Value (EV) 1 139,069 165,981 263,395 361,640 546,522 720,315 713,240 708,591
P/E ratio 14.8 x 24.9 x 45.1 x 53 x 101 x 57.4 x 42.8 x 33 x
Yield 1.96% 1.75% 1.23% 1.07% 0.78% 0.67% 0.77% 0.85%
Capitalization / Revenue 5.65 x 6.24 x 8.84 x 12.2 x 15.4 x 16.3 x 13.5 x 11.4 x
EV / Revenue 6.23 x 6.76 x 9.3 x 12.7 x 16 x 16.7 x 13.7 x 11.5 x
EV / EBITDA 18.4 x 19.3 x 26.3 x 38.2 x 63.7 x 44.4 x 34.1 x 26.5 x
EV / FCF 36.6 x 32.5 x 44.3 x 69.1 x 690 x 85.9 x 53.2 x 40.2 x
FCF Yield 2.73% 3.08% 2.26% 1.45% 0.15% 1.16% 1.88% 2.49%
Price to Book 48.3 x 28.6 x 29.4 x 32.7 x 48.9 x 40 x 24.7 x 16.6 x
Nbr of stocks (in thousands) 960,131 906,582 906,592 950,178 899,307 900,405 - -
Reference price 2 131.4 168.8 276.2 365.8 582.9 776.8 776.8 776.8
Announcement Date 1/30/20 1/29/21 2/3/22 2/2/23 2/6/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 22,320 24,540 28,318 28,541 34,124 43,031 51,947 61,552
EBITDA 1 7,551 8,589 10,005 9,472 8,584 16,240 20,945 26,727
EBIT 1 6,079 7,265 8,457 7,950 7,057 14,749 19,590 25,331
Operating Margin 27.24% 29.6% 29.86% 27.85% 20.68% 34.27% 37.71% 41.15%
Earnings before Tax (EBT) 1 5,266 7,230 6,156 6,806 6,555 14,404 17,518 20,548
Net income 1 8,318 6,194 5,582 6,245 5,240 12,029 16,090 21,020
Net margin 37.27% 25.24% 19.71% 21.88% 15.36% 27.95% 30.97% 34.15%
EPS 2 8.890 6.790 6.120 6.900 5.800 13.52 18.17 23.55
Free Cash Flow 1 3,803 5,112 5,951 5,230 792.5 8,386 13,415 17,634
FCF margin 17.04% 20.83% 21.01% 18.32% 2.32% 19.49% 25.82% 28.65%
FCF Conversion (EBITDA) 50.36% 59.52% 59.48% 55.21% 9.23% 51.64% 64.05% 65.98%
FCF Conversion (Net income) 45.71% 82.53% 106.61% 83.75% 15.12% 69.72% 83.38% 83.89%
Dividend per Share 2 2.580 2.960 3.400 3.920 4.520 5.193 5.993 6.587
Announcement Date 1/30/20 1/29/21 2/3/22 2/2/23 2/6/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 8,000 7,810 6,488 6,942 7,302 6,960 8,312 9,499 9,353 8,768 9,999 11,370 12,867 10,745 11,515
EBITDA 1 2,982 3,046 1,679 2,373 2,375 1,982 2,618 986.4 2,855 3,049 3,891 5,028 6,276 - -
EBIT 1 2,536 2,610 1,330 2,010 2,000 1,620 2,252 575.4 2,468 2,648 3,004 3,917 4,736 - -
Operating Margin 31.7% 33.42% 20.5% 28.96% 27.39% 23.27% 27.09% 6.06% 26.38% 30.2% 30.05% 34.45% 36.81% - -
Earnings before Tax (EBT) 1 - - - - - - 2,089 427.2 2,509 2,536 2,935 4,249 4,819 - -
Net income 1 1,726 1,903 952.5 1,452 1,938 1,345 1,763 -57.4 2,190 2,243 2,437 3,308 4,134 - -
Net margin 21.58% 24.36% 14.68% 20.91% 26.54% 19.32% 21.21% -0.6% 23.41% 25.58% 24.37% 29.09% 32.13% - -
EPS 2 1.900 - 1.050 1.610 2.140 1.490 1.950 -0.0600 2.420 2.480 2.745 3.656 4.556 - -
Dividend per Share 2 0.8500 0.9800 0.9800 0.9800 0.9800 1.130 1.130 1.130 1.130 1.300 1.300 1.300 1.299 - -
Announcement Date 2/3/22 4/28/22 8/4/22 11/1/22 2/2/23 4/27/23 8/8/23 11/2/23 2/6/24 4/30/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 12,879 12,914 12,976 14,027 22,298 20,925 13,851 9,201
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 1.706 x 1.504 x 1.297 x 1.481 x 2.598 x 1.288 x 0.6613 x 0.3443 x
Free Cash Flow 1 3,803 5,112 5,951 5,230 793 8,386 13,415 17,634
ROE (net income / shareholders' equity) 89.6% 175% 102% 73.2% 48.9% 82.7% 75.9% 69.2%
ROA (Net income/ Total Assets) 13.4% 14.4% 15.6% 14.6% 9.23% 17.7% 21.4% 25.3%
Assets 1 62,143 42,961 35,816 42,708 56,748 67,876 75,029 82,961
Book Value Per Share 2 2.720 5.900 9.410 11.20 11.90 19.40 31.40 46.70
Cash Flow per Share 2 5.170 7.120 7.960 7.830 4.690 15.40 20.00 25.20
Capex 1 1,034 1,388 1,310 1,854 3,448 3,704 2,788 2,888
Capex / Sales 4.63% 5.66% 4.63% 6.5% 10.1% 8.61% 5.37% 4.69%
Announcement Date 1/30/20 1/29/21 2/3/22 2/2/23 2/6/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Eli Lilly and Company

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
776.8 USD
Average target price
845.3 USD
Spread / Average Target
+8.83%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
NOVO NORDISK A/S Stock Novo Nordisk A/S
+25.07% 571B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.38% 364B
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.38% 326B
ABBVIE INC. Stock AbbVie Inc.
+3.70% 286B
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.68% 236B
NOVARTIS AG Stock Novartis AG
+4.71% 198B
ROCHE HOLDING AG Stock Roche Holding AG
-12.43% 194B
PFIZER, INC. Stock Pfizer, Inc.
-3.33% 154B
AMGEN INC. Stock Amgen Inc.
-3.54% 149B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. LLY Stock
  4. LLY Stock
  5. Financials Eli Lilly and Company